EP3307785A4 - Method for the in situ formation of bifunctional immunological complexes - Google Patents

Method for the in situ formation of bifunctional immunological complexes Download PDF

Info

Publication number
EP3307785A4
EP3307785A4 EP16806469.9A EP16806469A EP3307785A4 EP 3307785 A4 EP3307785 A4 EP 3307785A4 EP 16806469 A EP16806469 A EP 16806469A EP 3307785 A4 EP3307785 A4 EP 3307785A4
Authority
EP
European Patent Office
Prior art keywords
bifunctional
situ formation
immunological complexes
immunological
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16806469.9A
Other languages
German (de)
French (fr)
Other versions
EP3307785A1 (en
Inventor
Andy Isamu KOKAJI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemCell Technologies Inc
Original Assignee
StemCell Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by StemCell Technologies Inc filed Critical StemCell Technologies Inc
Publication of EP3307785A1 publication Critical patent/EP3307785A1/en
Publication of EP3307785A4 publication Critical patent/EP3307785A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP16806469.9A 2015-06-10 2016-06-03 Method for the in situ formation of bifunctional immunological complexes Withdrawn EP3307785A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173600P 2015-06-10 2015-06-10
PCT/CA2016/050631 WO2016197238A1 (en) 2015-06-10 2016-06-03 Method for the in situ formation of bifunctional immunological complexes

Publications (2)

Publication Number Publication Date
EP3307785A1 EP3307785A1 (en) 2018-04-18
EP3307785A4 true EP3307785A4 (en) 2018-12-05

Family

ID=57502731

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16806469.9A Withdrawn EP3307785A4 (en) 2015-06-10 2016-06-03 Method for the in situ formation of bifunctional immunological complexes

Country Status (4)

Country Link
US (1) US10983114B2 (en)
EP (1) EP3307785A4 (en)
CN (1) CN107709366B (en)
WO (1) WO2016197238A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108562739A (en) * 2018-04-23 2018-09-21 吉林大学 Target spot and hemoglobin bispecific immune complex and preparation and detection method
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
CN117659204B (en) * 2024-01-31 2024-06-11 山东微领生物有限公司 Tetrameric antibody complex and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868109A (en) * 1985-04-29 1989-09-19 Lansdorp Peter M Immunological antibody complex, its preparation and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117985A (en) * 1995-06-16 2000-09-12 Stemcell Technologies Inc. Antibody compositions for preparing enriched cell preparations
US6448075B1 (en) 1999-05-28 2002-09-10 Stemcell Technologies Inc. Method for separating cells using immunorosettes
US20020081635A1 (en) * 2000-05-11 2002-06-27 Thomas Terry E. Novel antibody compositions for preparing enriched T cell preparations
WO2007109747A2 (en) * 2006-03-21 2007-09-27 Wyeth Methods and compositions for antagonism of rage
EP2277181B1 (en) * 2008-04-16 2017-08-30 StemCell Technologies Inc. Magnetic particles
EP3594326B1 (en) * 2013-03-15 2023-11-15 Stemcell Technologies Inc. Method for separating cells using immunorosettes and particles
CN103305462B (en) * 2013-06-05 2015-05-20 南昌大学 Method for enriching and separating human peripheral blood CD34+ and CD91+ lymphocytes
US9970849B2 (en) * 2014-01-21 2018-05-15 Stemcell Technologies Inc. Method for separating target entities from a sample using a composition of mono-specific tetrameric antibody complexes coupled to a surface

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868109A (en) * 1985-04-29 1989-09-19 Lansdorp Peter M Immunological antibody complex, its preparation and its use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GORDON R ET AL: "A simple magnetic separation method for high-yield isolation of pure primary microglia", JOURNAL OF NEUROSCIENCE METHODS, ELSEVIER SCIENCE PUBLISHER B.V., AMSTERDAM, NL, vol. 194, no. 2, 15 January 2011 (2011-01-15), pages 287 - 296, XP027574484, ISSN: 0165-0270, [retrieved on 20101224] *
KUHARA M ET AL: "MAGNETIC CELL SEPARATION USING ANTIBODY BINDING WITH PROTEIN A EXPRESSED ON BACTERIAL MAGNETIC PARTICLES", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 76, no. 21, 1 November 2004 (2004-11-01), pages 6207 - 6213, XP001226098, ISSN: 0003-2700, DOI: 10.1021/AC0493727 *
See also references of WO2016197238A1 *

Also Published As

Publication number Publication date
US10983114B2 (en) 2021-04-20
WO2016197238A1 (en) 2016-12-15
US20180188245A1 (en) 2018-07-05
CN107709366A (en) 2018-02-16
EP3307785A1 (en) 2018-04-18
CN107709366B (en) 2021-10-26

Similar Documents

Publication Publication Date Title
AU2016388215B2 (en) Method for compressing point cloud
EP3531899A4 (en) Techniques for neuromodulation
EP3530435A4 (en) 3d bioprinter
EP3191178A4 (en) System and method for nested neurostimulation
EP3148729A4 (en) Hydride-coated microparticles and methods for making the same
EP3096936A4 (en) Three-dimensional object and method for forming same
EP3147105A4 (en) Formation device for forming three-dimensional structures
EP3126373A4 (en) Method for preparing amg 416
EP3127413A4 (en) Coordinated travel work system
EP3447730A4 (en) Three-dimensional reconstruction method
EP3126397A4 (en) Humanized antibodies that bind lgr5
EP3558312A4 (en) Methods for enhancing vascular density
EP3150711A4 (en) Method for preparing l-ergothioneine
EP3248704A4 (en) Flanging method
EP3119806A4 (en) Il-21 antibodies
EP3157634A4 (en) Antibodies that bind lgr4
EP3146594A4 (en) System and method for simple 2d phase-mode enabled beam-steering
EP3492158A4 (en) Backflushable depth filter
EP3442984A4 (en) Methods for detectingbordetella
EP3109246A4 (en) Thiopyranose compound and method for producing same
EP3233120A4 (en) Il-21 antibodies
EP3372388A4 (en) Method for forming three-dimensional object
EP3281742A4 (en) Polishing method
EP3307785A4 (en) Method for the in situ formation of bifunctional immunological complexes
EP3553048A4 (en) Method for producing -caprolactam

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181029

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/566 20060101ALI20181023BHEP

Ipc: C07K 16/46 20060101AFI20181023BHEP

Ipc: G01N 33/543 20060101ALI20181023BHEP

Ipc: C07K 16/42 20060101ALI20181023BHEP

Ipc: C07K 16/28 20060101ALI20181023BHEP

Ipc: C07K 16/00 20060101ALI20181023BHEP

Ipc: C12N 1/02 20060101ALI20181023BHEP

Ipc: G01N 33/53 20060101ALI20181023BHEP

Ipc: C07K 1/22 20060101ALI20181023BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190730

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20210916